RxDoctor Payments Data

Ursula Odimara

Psychiatric/Mental Health · Philadelphia, PANPI 1629490222

Payments from drug & device makers

$2,589in general payments, 2019–2025

Across 152 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$877
  • AbbVie$711
  • Teva Pharmaceuticals USA, Inc.$343
  • Otsuka America Pharmaceutical, Inc.$237
  • Vanda Pharmaceuticals Inc.$129
  • Neurocrine Biosciences, Inc.$117
  • plus $174 from 4 others

What the payments were for

  • Food & beverage$2,576100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,589 in reported general payments places this provider in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$10,293
Medicare patients
20
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aripiprazole149$11,821
FanaptIloperidone11$9,781
Atomoxetine Hcl27$4,664
Clozapine54$3,893
Quetiapine Fumarate161$2,764
Oxcarbazepine79$2,636
Perphenazine15$1,792
Methylphenidate ErMethylphenidate Hcl12$1,610
Fluphenazine Hcl12$1,498
Ziprasidone Hcl46$1,425
Fluvoxamine Maleate22$1,330
Benztropine Mesylate78$929
Trazodone Hcl141$795
Olanzapine52$774
Risperidone53$726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Fanapt$129$9,78111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →